DK2068874T3 - Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer - Google Patents

Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer Download PDF

Info

Publication number: DK2068874T3
Authority: DK; Denmark
Prior art keywords: myelomes; antibodies; methods; combination therapy; therapy based
Prior art date: 2006-08-07

Application number

DK07840746T

Other languages

English (en)

Inventor

Daniel Afar

Kenneth C Anderson

Yu-Tzu Tai

Original Assignee

Abbvie Biotherapeutics Inc

Dana Farber Cancer Inst Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-07

Filing date

2007-08-07

Publication date

2015-04-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2068874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-07 Application filed by Abbvie Biotherapeutics Inc, Dana Farber Cancer Inst Inc filed Critical Abbvie Biotherapeutics Inc

2015-04-27 Application granted granted Critical

2015-04-27 Publication of DK2068874T3 publication Critical patent/DK2068874T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK07840746T 2006-08-07 2007-08-07 Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer DK2068874T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83618506P	2006-08-07	2006-08-07
US94426207P	2007-06-15	2007-06-15
PCT/US2007/075403 WO2008019378A1 (en)	2006-08-07	2007-08-07	Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number	Publication Date
DK2068874T3 true DK2068874T3 (da)	2015-04-27

Family

ID=38831279

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13168383.1T DK2641601T3 (da)	2006-08-07	2007-08-07	Fremgangsmåder til behandling af multipelt myelom under anvendelse af kombinationsterapi baseret på HuLuc63 med bortezomib
DK07840746T DK2068874T3 (da)	2006-08-07	2007-08-07	Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13168383.1T DK2641601T3 (da)	2006-08-07	2007-08-07	Fremgangsmåder til behandling af multipelt myelom under anvendelse af kombinationsterapi baseret på HuLuc63 med bortezomib

Country Status (24)

Country	Link
US (4)	US8632772B2 (da)
EP (5)	EP2641601B8 (da)
JP (1)	JP5340935B2 (da)
CN (1)	CN101686971B (da)
AU (1)	AU2007281684C1 (da)
BR (1)	BRPI0716647A2 (da)
CA (1)	CA2660356C (da)
CY (5)	CY1116247T1 (da)
DK (2)	DK2641601T3 (da)
ES (2)	ES2535437T3 (da)
HK (1)	HK1129853A1 (da)
HR (2)	HRP20150449T1 (da)
HU (4)	HUE029027T2 (da)
IL (2)	IL196919A (da)
LT (4)	LT2641601T (da)
LU (3)	LU93276I2 (da)
MX (1)	MX2009001441A (da)
NL (1)	NL300840I2 (da)
NO (1)	NO346835B1 (da)
NZ (1)	NZ574978A (da)
PL (2)	PL2068874T3 (da)
PT (2)	PT2641601T (da)
SI (2)	SI2068874T1 (da)
WO (1)	WO2008019378A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2641601T (pt)	2006-08-07	2016-10-14	Dana Farber Cancer Inst Inc	Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
EP2425849A3 (en) *	2006-08-07	2012-05-09	Abbott Biotherapeutics Corp.	Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
JP2011523560A (ja) *	2008-06-02	2011-08-18	ダナ−ファーバーキャンサーインスティテュートインク．	Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
US8563700B2 (en) *	2008-06-16	2013-10-22	Immunogen, Inc.	Synergistic effects
AP2011005690A0 (en) *	2008-10-21	2011-06-30	Onyx Therapeutics Inc	Combination therapy with peptide epoxyketones.
AU2010293383B2 (en) *	2009-09-10	2014-12-18	Kyowa Kirin Co., Ltd.	Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4)
US8841325B2 (en) *	2009-11-24	2014-09-23	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
CN102241773B (zh) *	2010-05-13	2014-05-14	四川大学	抗骨髓瘤细胞多克隆抗体及其制备方法
CN105377288B (zh)	2012-11-05	2019-11-15	达纳-法伯癌症研究所股份有限公司	Xbp1、cd138和cs1肽的组合物制备药物的用途
WO2015069785A1 (en) *	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
WO2015069703A1 (en)	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
EP3783020A1 (en) *	2013-11-21	2021-02-24	F. Hoffmann-La Roche AG	Anti-alpha-synuclein antibodies and methods of use
HRP20230265T1 (hr) *	2014-08-22	2023-04-14	Celgene Corporation	Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
WO2016049022A1 (en) *	2014-09-23	2016-03-31	Board Of Trustees Of Michigan State University	Compositions and methods for modulating an immune response
WO2016054354A1 (en)	2014-10-02	2016-04-07	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating malignancies
CA2966005C (en)	2014-10-31	2021-04-27	Abbvie Biotherapeutics Inc.	Anti-cs1 antibodies and antibody drug conjugates
WO2016073184A1 (en)	2014-11-04	2016-05-12	Dana Farber Cancer Institute, Inc.	Compositions and methods for treating multiple myeloma
MX2017007097A (es) *	2014-12-04	2017-09-05	Bristol Myers Squibb Co	Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
CA2984464C (en) *	2015-05-13	2023-10-10	Morphosys Ag	Treatment for multiple myeloma (mm)
BR112017027692A2 (pt)	2015-06-29	2018-10-09	Bristol Myers Squibb Co	regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer
CN109432398A (zh) *	2016-03-13	2019-03-08	曹帅	一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11124579B2 (en)	2017-03-29	2021-09-21	Agency For Science, Technology And Research	Anti oligosaccharide antibody
AU2018372924A1 (en) *	2017-11-22	2020-04-23	Hillstream Biopharma Inc.	Polymeric nanoparticles comprising bortezomib
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
CN115298549A (zh)	2019-11-05	2022-11-04	百时美施贵宝公司	M蛋白测定及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112969A (en)	1994-03-17	2001-05-20	Baxter Int	Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
EP0831860B1 (en)	1995-05-25	2004-10-20	Baxter International Inc.	Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
CA2752140A1 (en) *	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7709610B2 (en) *	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) *	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) *	2004-11-04	2009-07-09	Avner Yayon	Treatment of b-cell malignancies
PT2641601T (pt)	2006-08-07	2016-10-14	Dana Farber Cancer Inst Inc	Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
EP2425849A3 (en) *	2006-08-07	2012-05-09	Abbott Biotherapeutics Corp.	Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
US20080095768A1 (en)	2006-08-07	2008-04-24	Pdl Biopharma, Inc.	Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

2007
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/da active
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en active Application Filing
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
- 2009-10-23 HK HK09109870.7A patent/HK1129853A1/xx unknown
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-04-27 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I1/el unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL243933A0 (en)	2016-04-21
NO20090968L (no)	2009-04-30
HK1129853A1 (en)	2009-12-11
LU93277I2 (fr)	2016-12-27
HRP20150449T1 (en)	2015-06-05
ES2535437T3 (es)	2015-05-11
JP2010500371A (ja)	2010-01-07
NO346835B1 (no)	2023-01-23
HUS1600043I1 (hu)	2016-12-28
CY2016036I2 (el)	2017-07-12
EP2942057A1 (en)	2015-11-11
US20170342150A1 (en)	2017-11-30
CN101686971B (zh)	2013-09-11
US20160137735A1 (en)	2016-05-19
CY1117992T1 (el)	2017-05-17
AU2007281684B2 (en)	2013-05-16
EP2068874B1 (en)	2015-01-28
NZ574978A (en)	2012-08-31
PT2068874E (pt)	2015-05-21
DK2641601T3 (da)	2016-08-22
SI2068874T1 (sl)	2015-06-30
JP5340935B2 (ja)	2013-11-13
CY2016037I1 (el)	2017-07-12
AU2007281684A1 (en)	2008-02-14
LT2641601T (lt)	2016-10-10
LTPA2016030I1 (lt)	2016-11-10
CA2660356A1 (en)	2008-02-14
NL300840I2 (da)	2017-01-03
CY2016038I1 (el)	2017-07-12
EP2641601A1 (en)	2013-09-25
PL2068874T3 (pl)	2015-06-30
HUS1600045I1 (hu)	2016-12-28
CN101686971A (zh)	2010-03-31
HRP20161284T1 (hr)	2016-12-16
EP2641600A1 (en)	2013-09-25
EP2641601B1 (en)	2016-07-06
CY2016036I1 (el)	2017-07-12
EP3115049A1 (en)	2017-01-11
BRPI0716647A2 (pt)	2017-05-16
AU2007281684C1 (en)	2013-12-19
SI2641601T1 (sl)	2016-11-30
ES2589302T3 (es)	2016-11-11
LTPA2016031I1 (lt)	2016-11-10
US8632772B2 (en)	2014-01-21
EP2641601B8 (en)	2016-09-21
IL196919A0 (en)	2009-11-18
CY1116247T1 (el)	2017-02-08
IL196919A (en)	2016-03-31
EP2068874A1 (en)	2009-06-17
PT2641601T (pt)	2016-10-14
LU93276I2 (fr)	2016-12-27
US20140322201A1 (en)	2014-10-30
HUS1600044I1 (hu)	2016-12-28
LTC2068874I2 (lt)	2018-11-12
MX2009001441A (es)	2009-07-06
PL2641601T3 (pl)	2017-01-31
CA2660356C (en)	2016-04-05
HUE029027T2 (en)	2017-01-30
US20080152646A1 (en)	2008-06-26
LU93275I2 (fr)	2016-12-27
WO2008019378A1 (en)	2008-02-14
LTPA2016029I1 (lt)	2016-11-10

Publication	Publication Date	Title
DK2068874T3 (da)	2015-04-27	Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
DK1874821T3 (da)	2013-07-08	Kombination af antistoffer med glykokortikoider til behandling af kræft
DK2781593T3 (da)	2019-10-21	Fremgangsmåde til behandling af methanemissioner
DK2101819T3 (da)	2013-04-29	Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK2212070T3 (da)	2013-07-08	Fremgangsmåde til behandling af træ
DK1877232T3 (da)	2014-08-11	Fremgangsmåde til behandling af træoverflader
DK1999225T3 (da)	2010-09-06	Fremgangsmåder til behandling af borehuller med genanvendelige fluider
DK2545939T3 (da)	2021-02-15	Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer
DK1874781T3 (da)	2009-11-02	Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2081669T3 (da)	2019-01-02	Fremgangsmåde og anordning til fremstilling af granulater
DK1986633T3 (da)	2014-11-03	Behandling af duchennes muskeldystrofi
DK2073811T3 (da)	2015-06-22	Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
DK2240137T3 (da)	2021-06-07	Apparat til behandling af fedme
DK2293816T3 (da)	2013-02-04	Fremgangsmåder til behandling af reumatoid arthritis
DK2086944T3 (da)	2010-05-03	Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2001892T3 (da)	2013-07-01	Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK2034830T3 (da)	2014-10-27	Anti-vla-1-antistof til behandling af slagtilfælde
DK3403657T3 (da)	2022-02-28	Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
DK2164572T3 (da)	2013-02-11	Carbamoyl-cyclohexaner til behandling af akut mani
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2131841T3 (da)	2012-10-15	Fremgangsmåder til behandling af akut smerte
DK1814555T3 (da)	2009-12-07	S-mirtazapin til behandling af hedeture
DK2012814T3 (da)	2013-08-19	Fremgangsmåder til behandling af autoimmunsygdomme
DK2323686T3 (da)	2013-06-03	Adiponectin til behandling af lungesygdom